Allergan touts 5-year data for Liletta intrauterine contraceptive

Allergan (NYSE:AGN) and its nonprofit partner, Medicines360, touted five-year data today from an on-going pivotal trial of its intrauterine device, Liletta.

The levonorgestrel-releasing contraceptive is approved in the U.S. to be used to prevent pregnancy for up to four years.